{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:47:09Z","timestamp":1788871629407,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ctrv.2014.12.011","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T02:31:22Z","timestamp":1419906682000},"page":"94-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2\u2212 advanced breast cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Guy","family":"Jerusalem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-667X","authenticated-orcid":false,"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2014.12.011_b0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrclinonc.2013.29","article-title":"Emerging targeted agents in metastatic breast cancer","volume":"10","author":"Zardavas","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"9114","key":"10.1016\/j.ctrv.2014.12.011_b0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists\u2019 Collaborative Group","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.ctrv.2014.12.011_b0015","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2014.56.7479","article-title":"Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"32","author":"Partridge","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.12.011_b0020","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"25","author":"Cardoso","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.12.011_b0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1677\/erc.1.00776","article-title":"Mechanisms of tamoxifen resistance","volume":"11","author":"Ring","year":"2004","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2014.12.011_b0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC 1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.ctrv.2014.12.011_b0035","doi-asserted-by":"crossref","first-page":"542","DOI":"10.6004\/jnccn.2014.0058","article-title":"Breast cancer version 3.2014","volume":"12","author":"Gradishar","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"33","key":"10.1016\/j.ctrv.2014.12.011_b0040","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2014.12.011_b0045","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1210\/endo.141.1.7270","article-title":"Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo","volume":"141","author":"Shim","year":"2000","journal-title":"Endocrinology"},{"issue":"43","key":"10.1016\/j.ctrv.2014.12.011_b0050","doi-asserted-by":"crossref","first-page":"40080","DOI":"10.1074\/jbc.M105892200","article-title":"Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells","volume":"276","author":"Stephen","year":"2001","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.ctrv.2014.12.011_b0055","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1074\/jbc.M010840200","article-title":"Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance","volume":"276","author":"Campbell","year":"2001","journal-title":"J Biol Chem"},{"issue":"7092","key":"10.1016\/j.ctrv.2014.12.011_b0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ctrv.2014.12.011_b0065","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/CCO.0b013e328358a2b5","article-title":"Phosphatidylinositol 3-kinase\/AKT\/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+\/HER2\u2212) breast cancers?","volume":"24","author":"Zardavas","year":"2012","journal-title":"Curr Opin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2014.12.011_b0070","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","article-title":"Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity","volume":"10","author":"de Graffenried","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ctrv.2014.12.011_b0075","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1158\/1078-0432.CCR-04-2402","article-title":"Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer","volume":"11","author":"Boulay","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2014.12.011_b0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ctrv.2014.12.011_b0085","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","article-title":"FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.12.011_b0090","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2014.12.011_b0095","first-page":"S399","article-title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer \u2013 final analysis LEA study","volume":"49","author":"Loibl","year":"2013","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2014.12.011_b0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2014.12.011_b0105","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.ctrv.2014.12.011_b0110","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2014.12.011_b0115","article-title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer-first efficacy results from the LEA study","volume":"72","author":"Martin","year":"2012","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2014.12.011_b0120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2014.12.011_b0125","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s10637-009-9257-1","article-title":"Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer","volume":"28","author":"Buckner","year":"2010","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.ctrv.2014.12.011_b0130","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-013-2814-5","article-title":"Everolimus plus exemestane as first-line therapy in HR(+), HER2(\u2212) advanced breast cancer in BOLERO-2","volume":"143","author":"Beck","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2014.12.011_b0135","article-title":"Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2","volume":"31","author":"Hortobagyi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2014.12.011_b0140","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdu009","article-title":"Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2","volume":"25","author":"Rugo","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2014.12.011_b0145","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2014.12.011_b0150","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1185\/03007995.2013.836078","article-title":"Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(\u2212) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy","volume":"29","author":"Campone","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ctrv.2014.12.011_b0155","series-title":"Afinitor [package insert]","year":"2014"},{"key":"10.1016\/j.ctrv.2014.12.011_b0160","series-title":"Afinitor 2.5mg tablets [summary of product characteristics]","year":"2013"},{"issue":"10","key":"10.1016\/j.ctrv.2014.12.011_b0165","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2014.12.011_b0170","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2014.12.011_b0175","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.ctrv.2014.12.011_b0180","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res"},{"issue":"5712","key":"10.1016\/j.ctrv.2014.12.011_b0185","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ctrv.2014.12.011_b0190","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ctrv.2014.12.011_b0195","unstructured":"ClinicalTrials.gov. Phase III study of BKM120\/placebo with fulvestrant in postmenopausal patients with hormone receptor positive HER2-negative locally advanced or metastatic breast cancer refractory to aromatase inhibitor (BELLE-2). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01610284?term=BELLE-2&rank=1 [accessed 14.10.14]."},{"key":"10.1016\/j.ctrv.2014.12.011_b0200","author":"Iwata","year":"2013"},{"key":"10.1016\/j.ctrv.2014.12.011_b0205","unstructured":"ClinicalTrials.gov. A phase III study of BKM120 with fulvestrant in patients with HR+, HER2\u2212, AI treated, locally advanced or metastatic breast cancer who progressed on or after mTORi (BELLE-3). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01633060?term=BELLE-3&rank=1 [accessed 14.10.14]."},{"key":"10.1016\/j.ctrv.2014.12.011_b0210","unstructured":"ClinicalTrials.gov. A study of palbociclib (PD-0332991) + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+\/HER2\u2212 advanced breast cancer (PALOMA-2). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01740427?term=palbociclib+breast+cancer&rank=2&submit_fld_opt= [accessed 14.10.14]."},{"key":"10.1016\/j.ctrv.2014.12.011_b0215","unstructured":"ClinicalTrials.gov. Palbociclib (PD-0332991) combined with fulvestrant in hormone receptor+ HER2-negative metastatic breast cancer after endocrine failure (PALOMA-3). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01942135?term=palbociclib+breast+cancer&rank=1&submit_fld_opt= [accessed 14.10.14]."},{"key":"10.1016\/j.ctrv.2014.12.011_b0220","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer (MONALEESA-2). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01958021?term=MONALEESA-2&rank=1 [accessed 14.10.14]."},{"key":"10.1016\/j.ctrv.2014.12.011_b0225","unstructured":"ClinicalTrials.gov. A study of LY2835219 combined with fulvestrant in women with hormone receptor positive HER2 negative breast cancer (MONARCH 2). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02107703?term=MONARCH+2&rank=1 [accessed 14.10.14]."},{"key":"10.1016\/j.ctrv.2014.12.011_b0230","unstructured":"ClinicalTrials.gov. Exemestane with or without entinostat in treating postmenopausal patients with recurrent hormone receptor-positive breast cancer that is locally advanced or metastatic. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02115282?term=Entinostat+breast+cancer&rank=4 [accessed 14.10.14]."},{"issue":"5","key":"10.1016\/j.ctrv.2014.12.011_b0235","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-10-1869","article-title":"Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study","volume":"17","author":"Osborne","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2014.12.011_b0240","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-09-2282","article-title":"Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer","volume":"16","author":"Cristofanilli","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2014.12.011_b0245","article-title":"Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT)","volume":"31","author":"Johnston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2014.12.011_b0250","article-title":"A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+\/PR+, HER2-negative breast cancer","volume":"32","author":"Higgins","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2014.12.011_b0255","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(13)70026-3","article-title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","volume":"14","author":"Robertson","year":"2013","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2014.12.011_b0260","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1158\/1078-0432.CCR-11-1151","article-title":"Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer","volume":"17","author":"Ibrahim","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ctrv.2014.12.011_b0265","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.011_b0270","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","author":"Finn","year":"2014","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2014.12.011_b0275","article-title":"Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4\/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+, HER2\u2013advanced breast cancer (TRIO-18)","volume":"72","author":"Finn","year":"2012","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.ctrv.2014.12.011_b0280","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"Yardley","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.011_b0285","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS13-S3-07","article-title":"Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy","author":"Paul","year":"2013"},{"issue":"5","key":"10.1016\/j.ctrv.2014.12.011_b0290","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"14","key":"10.1016\/j.ctrv.2014.12.011_b0295","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4161\/cc.21195","article-title":"Therapeutic response to CDK4\/6 inhibition in breast cancer defined by ex vivo analyses of human tumors","volume":"11","author":"Dean","year":"2012","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.ctrv.2014.12.011_b0300","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-010-1312-2","article-title":"Significance of ER-Src axis in hormonal therapy resistance","volume":"130","author":"Vallabhaneni","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"24 Suppl. 3","key":"10.1016\/j.ctrv.2014.12.011_b0305","article-title":"Randomized phase II trial of fulvestrant with or without dasatinib in postmenopausal patients with hormone receptor-positive metastatic breast cancer previously treated with an aromatase inhibitor","volume":"71","author":"Wright","year":"2011","journal-title":"Cancer Res"},{"issue":"24 Suppl. 3","key":"10.1016\/j.ctrv.2014.12.011_b0310","article-title":"Randomized phase II study of dasatinib vs placebo in addition to exemestane in advanced ER\/PR-positive breast cancer [BMS CA180-261 study]","volume":"71","author":"Llombart","year":"2011","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2014.12.011_b0315","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/0008-5472.CAN-10-2458","article-title":"Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole","volume":"71","author":"Sabnis","year":"2011","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.ctrv.2014.12.011_b0320","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214002163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214002163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:19:28Z","timestamp":1759655968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214002163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0305737214002163"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.12.011","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2\u2212 advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}